New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
13:08 EDTINSYInsys Therapeutics weakness a buying opportunity, says JMP Securities
JMP Securities said Insys Therapeutics (INSY) is weak on concerns that Subsys may be added to Express Scripts' (ESRX) exclusion list in 2015. The analyst does not know if it will or not be added but said the potential impact would not be material to sales or growth because the product is not included in any PBM preferred formula positions and has prior authorization requirements. The analyst would use weakness as a buying opportunity and reiterates its Outperform rating and $65 price target.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
07:30 EDTINSYDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 23, 2015
10:31 EDTINSYInsys Therapeutics management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use